ClinicalTrials.gg
CompletedNCT02317705Updated Jun 21, 2022Results posted

Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

A Phase 2 interventional study of OTL38 and Near infrared camera imaging system in Ovarian Cancer, sponsored by On Target Laboratories, LLC. Completed at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-21.

Sponsored by On Target Laboratories, LLC · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Enrollment
733rd of 1,498
48 · median 47
Started
2014
with 57 others
Phase 2
485 of 1,779
53 open now
Registered
857th of 1,779
by date

Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 733rd largest by enrollment of the 1,498 interventional ones that give a count, is one of 58 that started in 2014, is one of 485 in phase 2, and was the 857th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

273 more — sign in →

All 278 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,779 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is being done to:

  • test the safety of OTL38
  • see if OTL38 helps light up the cancer when viewed with the special camera system
  • test the safety of the special camera system for use along with OTL38 during surgery
03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients 18 years of age and older
  2. Have a primary diagnosis, or at high clinical suspicion, of primary ovarian cancer (of epithelial type), planned for primary debulking or interval debulking surgery, and:

    • Who are scheduled to undergo laparotomy for the debulking surgery OR
    • Who are scheduled to undergo laparoscopy and pre-authorized to undergo laparotomy for the debulking surgery, if cancer is detected on the laparoscopy
  3. A negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of
  4. Female patients of childbearing potential or less than 2 years agree to use an acceptable form of from the time of signing until 30 days after study completion
  5. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments

Exclusion criteria

Exclusion Criteria:

  1. Previous exposure to OTL38
  2. Known FR alpha-negative ovarian cancer
  3. Planned surgical approach via laparoscopy or robotic surgery
  4. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the patient
  5. History of anaphylactic reactions or severe allergies
  6. History of allergy to any of the components of OTL38, including folic acid
  7. Pregnancy, or positive pregnancy test
  8. abnormalities on (ECG)
  9. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  10. Impaired renal function defined as \< 50 mL/min/1.73m2
  11. Impaired liver function defined as values > 3x the (ULN) for (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total .
  12. Known Stage IV ovarian cancer with
  13. Received an agent in another investigational drug or vaccine trial within 30 days prior to surgery
  14. Known sensitivity to fluorescent light
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Patients Receiving OTL38

    All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.

    Drug: OTL38 · Device: Near infrared camera imaging system · Procedure: Laparotomy

Interventions

  • DrugOTL38

    Also known as: OTL38 for Injection, CYTALUX™ (pafolacianine) injection

  • DeviceNear infrared camera imaging system

    Near infrared camera imaging system

  • ProcedureLaparotomy

    primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery

06

What researchers measure

Primary outcomes

  1. Sensitivity of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer During Surgery.

    Sensitivity for the detection of folate receptor-alpha positive (FRAP) ovarian cancer lesions is defined as the ratio (multiplied by 100) of the number of FRAO ovarian cancer lesions confirmed by both fluorescent light and the pathology/ and immunohistochemistry lab (TP) over the number of FRAP ovarian cancer lesions confirmed by the pathology/ and immunohistochemistry lab (TP+FN). 95% lower one-sided confidence interval was used.

    Time frame: Day of Surgery (Day 1)

  2. Positive Predictive Value (PPV) of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer During Surgery.

    PPV for the detection of FRAP ovarian cancer lesions is defined as the ratio (multiplied by 100) of the number of FRAP ovarian cancer lesions confirmed by both fluorescent light and the pathology/ and immunohistochemistry lab (TP) over the number of FRAP ovarian cancer lesions confirmed by fluorescent light (TP + FP). 95% lower one-sided confidence interval was used.

    Time frame: Day of Surgery (Day 1)

07

Results

Posted Jun 21, 2022

Participant flow

Participant flow — Overall Study
MilestoneOTL38 for Intra-operativeImaging of Folate Receptor-alpha Positive Ovarian Cancer
Started48
Safety population44
Modified intent-to-treat (mitt)29
Completed43
Not completed5
Withdrew: Withdrawal by subject3
Withdrew: Physician decision1
Withdrew: Drug not usable1

Outcome measures

PrimarySensitivity of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer During Surgery.

Sensitivity for the detection of folate receptor-alpha positive (FRAP) ovarian cancer lesions is defined as the ratio (multiplied by 100) of the number of FRAO ovarian cancer lesions confirmed by both fluorescent light and the pathology/ and immunohistochemistry lab (TP) over the number of FRAP ovarian cancer lesions confirmed by the pathology/ and immunohistochemistry lab (TP+FN). 95% lower one-sided confidence interval was used.

Time frame:
Day of Surgery (Day 1)
Reported as:
Number · percentage of lesions
Sensitivity of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer During Surgery.
percentage of lesionsExperimental
Sensitivity of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer During Surgery.97.97 (87.75 to NA)
PrimaryPositive Predictive Value (PPV) of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer During Surgery.

PPV for the detection of FRAP ovarian cancer lesions is defined as the ratio (multiplied by 100) of the number of FRAP ovarian cancer lesions confirmed by both fluorescent light and the pathology/ and immunohistochemistry lab (TP) over the number of FRAP ovarian cancer lesions confirmed by fluorescent light (TP + FP). 95% lower one-sided confidence interval was used.

Time frame:
Day of Surgery (Day 1)
Reported as:
Number · percentage of lesions
Positive Predictive Value (PPV) of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer During Surgery.
percentage of lesionsExperimental
Positive Predictive Value (PPV) of OTL38 in Detecting Folate Receptor-alpha Positive Ovarian Cancer During Surgery.94.93 (86.13 to NA)

Adverse events

Collected over Adverse events were collected from the time of study drug administration throughout the course of the study, ending with Visit 4. The total collection period for each subject was approximately one month.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients Receiving OTL380/44 (0%)13/44 (29.5%)44/44 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPatients Receiving OTL38
Postoperative wound infectionInfections and infestations2/44
SepsisInfections and infestations2/44
Clostridium difficile infectionInfections and infestations1/44
Haematoma infectionInfections and infestations1/44
PneumoniaInfections and infestations1/44
Septic ShockInfections and infestations1/44
Wound abscessInfections and infestations1/44
ConstipationGastrointestinal disorders1/44
NauseaGastrointestinal disorders1/44
Small intestinal obstructionGastrointestinal disorders1/44
Most frequent other events
Showing 10 of 87
Most frequent other events
EventPatients Receiving OTL38
Procedural painInjury, poisoning and procedural complications40/44
VomitingGastrointestinal disorders14/44
NauseaGastrointestinal disorders12/44
AnaemiaBlood and lymphatic system disorders11/44
HypokalaemiaMetabolism and nutrition disorders7/44
Infusion related reactionInjury, poisoning and procedural complications5/44
PyrexiaGeneral disorders5/44
Sinus tachycardiaCardiac disorders5/44
Abdominal distensionGastrointestinal disorders4/44
ConstipationGastrointestinal disorders4/44

Baseline characteristics

Number of enrolled subjects

Age, Categorical
Age, Categorical(Participants)OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
<=18 years0
Between 18 and 65 years23
>=65 years21
Age, Continuous
Age, Continuous(years)OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Mean63.8 ± 10.19
Sex: Female, Male
Sex: Female, Male(Participants)OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Female44
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Hispanic or Latino0
Not Hispanic or Latino37
Unknown or Not Reported7
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White35
More than one race1
Unknown or Not Reported4
Region of Enrollment
Region of Enrollment(participants)OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
United States44
08

Study locations

4 sites
  • University of CA at Irvine Chao Cancer Center
    Orange, California 92868, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Mayo Clinic-Rochester
    Rochester, Minnesota 55905, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD008765. doi: 10.1002/14651858.CD008765.pub3. PubMed 23450588 ↗
  • Crane LM, Arts HJ, van Oosten M, Low PS, van der Zee AG, van Dam GM, Bart J. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr). 2012 Feb;35(1):9-18. doi: 10.1007/s13402-011-0052-6. Epub 2011 Jun 7. Erratum In: Cell Oncol (Dordr). 2012 Jun;35(3):229. PubMed 21647742 ↗
  • Ibeanu OA, Bristow RE. Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: a review. Int J Gynecol Cancer. 2010 Jan;20 Suppl 1:S1-11. doi: 10.1111/IGC.0b013e3181cff38b. PubMed 20065732 ↗
  • Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008 Mar;108(3):619-26. doi: 10.1016/j.ygyno.2007.11.020. Epub 2008 Jan 28. PubMed 18222534 ↗
  • Leamon CP, Low PS. Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biochem J. 1993 May 1;291 ( Pt 3)(Pt 3):855-60. doi: 10.1042/bj2910855. PubMed 8387781 ↗
  • Markert S, Lassmann S, Gabriel B, Klar M, Werner M, Gitsch G, Kratz F, Hasenburg A. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 2008 Nov-Dec;28(6A):3567-72. PubMed 19189636 ↗
  • Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005 Mar 15;338(2):284-93. doi: 10.1016/j.ab.2004.12.026. PubMed 15745749 ↗
  • Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994 May 1;73(9):2432-43. doi: 10.1002/1097-0142(19940501)73:93.0.co;2-s. PubMed 7513252 ↗
  • Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol. 2010 Jun;21(2):75-80. doi: 10.3802/jgo.2010.21.2.75. Epub 2010 Jun 30. PubMed 20613895 ↗
  • Toffoli G, Russo A, Gallo A, Cernigoi C, Miotti S, Sorio R, Tumolo S, Boiocchi M. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer. 1998 Apr 17;79(2):121-6. doi: 10.1002/(sici)1097-0215(19980417)79:23.0.co;2-v. PubMed 9583724 ↗
  • van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, Sarantopoulos A, de Jong JS, Arts HJ, van der Zee AG, Bart J, Low PS, Ntziachristos V. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med. 2011 Sep 18;17(10):1315-9. doi: 10.1038/nm.2472. PubMed 21926976 ↗
  • Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr, Kamen BA. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992 Jun 15;52(12):3396-401. PubMed 1596899 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2022, 6 years 7 months after primary completion. A results delay was requested in Aug 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2014
First posted
Dec 16, 2014
Start
Dec 2014
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results delay requested
Aug 28, 2019
Results first posted
Jun 21, 2022
Last update
Jun 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02317705
Lead sponsor
On Target Laboratories, LLC
Collaborators
SynteractHCR
Responsible party
Sponsor
First posted
Dec 16, 2014
Start date
Dec 2014
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Jun 21, 2022
Last update
Jun 21, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pafolacianine

Start the discussion